Learn more about our Diagnostics work.
Today, AdvaMed®, the medtech association, released the following statement from President and CEO Scott Whitaker on the introduction of the bipartisan Ensuring Patient Access to Critical Breakthrough Products Act. The…
AdvaMedDx®, a division of AdvaMed® representing more than 75 manufacturers of innovative in vitro diagnostic (IVD) tests and technologies in the U.S. and abroad, announced today that Thierry Bernard, CEO…
It is critical for diagnostic test developers to demonstrate the value of their tests to a variety of stakeholders. This framework serves as a resource for members to assess and…
AdvaMed®, joined by American Cancer Society Cancer Action Network, The Pew Charitable Trust, Friends of Cancer Research, and other, sent a letter urging the leaders of the Senate Committee on Health,…
AdvaMed®, the world’s largest trade organization representing medical technology companies and innovators, announced today that the AdvaMedDx® Board of Directors unanimously selected Zach Rothstein as AdvaMedDx®’s new Executive Director. In…
The VALID Act is carefully tailored to ensure continued access to tests offered by academic medical centers and other laboratories.
October is Breast Cancer Awareness Month and a good time to remember the importance of diagnostic screenings in saving lives.
This report outlines a key data-driven summary of the U.S. COVID testing supply.
CEO and surgeon Dr. Lishan Aklog speaks about the tremendous value of medical technology, the sharp disparities patients face, and the importance of policymaking to ease those disparities.
AdvaMed® submitted a letter to Medicare Administrative Contractors, Novitas and First Coast Service Options, regarding proposed LCDs on Genetic Testing in Oncology.